Table 2.
Univariate analysis of prognostic factors for patients with lung adenocarcinoma in Henan, China, 2017.
| Factor | Person-years | Cases | Case fatality rate (%) | HR1 | 95% CI2 | P value |
|---|---|---|---|---|---|---|
| Total | 421.3 | 233 | 55.3 | |||
| Age | ||||||
| <65 | 263.7 | 129 | 48.9 | 1.00 | ||
| ≥65 | 157.7 | 104 | 65.9 | 1.37 | 1.05–1.78 | 0.019 |
|
| ||||||
| Sex | ||||||
| Man | 201.8 | 120 | 59.5 | 1.00 | ||
| Women | 219.5 | 113 | 51.5 | 0.87 | 0.67–1.12 | 0.280 |
|
| ||||||
| TNM3 stage | ||||||
| I–III | 228.9 | 85 | 37.1 | 1.00 | ||
| IV | 192.5 | 148 | 76.9 | 2.16 | 1.65–2.82 | <0.001 |
|
| ||||||
| KPS4 scores | ||||||
| ≥80 | 269.5 | 115 | 42.7 | 1.00 | ||
| <80 | 151.8 | 118 | 77.7 | 1.88 | 1.45–2.43 | <0.001 |
|
| ||||||
| Lung lobectomy | ||||||
| Yes | 172.2 | 49 | 28.5 | 1.00 | ||
| No | 249.1 | 184 | 73.9 | 2.78 | 2.02–3.83 | <0.001 |
|
| ||||||
| Chemotherapy | ||||||
| Yes | 248.4 | 117 | 47.1 | 1.00 | ||
| No | 173.0 | 116 | 67.1 | 1.48 | 1.14–1.91 | 0.003 |
|
| ||||||
| Radiotherapy | ||||||
| Yes | 71.6 | 32 | 44.7 | 1.00 | ||
| No | 349.7 | 201 | 57.5 | 1.33 | 0.92–1.94 | 0.132 |
|
| ||||||
| Smoking | ||||||
| No | 260.2 | 138 | 53.0 | 1.00 | ||
| Yes | 161.1 | 95 | 59.0 | 1.09 | 0.84–1.42 | 0.500 |
|
| ||||||
| Alcohol | ||||||
| No | 382.9 | 200 | 52.2 | 1.00 | ||
| Yes | 38.5 | 33 | 85.7 | 1.69 | 1.17–2.45 | 0.006 |
|
| ||||||
| Family history | ||||||
| No | 385.9 | 218 | 56.5 | 1.00 | ||
| Yes | 35.4 | 15 | 42.4 | 0.73 | 0.43–1.24 | 0.248 |
|
| ||||||
| Hemoglobin5 | ||||||
| NPHb | 367.1 | 189 | 51.5 | 1.00 | ||
| LPHb | 54.3 | 44 | 81.0 | 1.61 | 1.16–2.24 | 0.004 |
1HR: hazard ratio by multivariate Cox proportional hazards regression. 2CI: confidence interval. 3TNM: tumor-node-metastasis. 4KPS: Karnofsky performance status. 5Hemoglobin: NPHb (normal pretreatment hemoglobin): men 120–160 g/l and women 110–150 g/l; LPHb (low pretreatment hemoglobin): men < 120 g/l and women ≤ 110 g/l.